Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck-Teva Legal Wrangle Over Januvia "R&D" In India

Executive Summary

Merck & Co continues to keep a hawk eye on alleged infringement activities in India pertaining to its diabetes therapies Januvia (sitagliptin) and Janumet (sitagliptin/metformin hydrochloride). It has hauled Teva to court for allegedly manufacturing and selling sitagliptin, though the Israeli multinational has claimed that its efforts were geared only towards regulatory submissions.


Related Content

Legal Wrangles: Foreign Firms Gaming The System In India?
Merck Wards Off More Januvia Infringers In India
Permanent Bar Against Glenmark's Sitagliptin Copies


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts